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A Survey of Isosteric Amide Replacements in a Series of Extended, Hydroxamate-containing, 
Selective MMP-13 Inhibitors
Thomas E. Barta, Daniel P. Becker, Louis J. Bedell, Alan M. Easton, Susan L. Hockerman, 
James Kiefer, Grace E. Munie, Karl J. Mathis, Madeleine H. Li, Joseph G. Rico, Clara I. 
Villamil,  Jennifer M. Williams
Abstract: Seeking compounds preferentially potent and selective for MMP-13, we recently 
reported on a series of hydroxamic acids with a flexible benzamide tail groups.1 In this Letter, we 
replace the amide moiety with non-hydrolyzable heterocycles in an effort to improve half-life. 
We identify a hydroxamate tetrazole 4e that spares MMP-1 and -14,  shows >400 fold selectivity 
vs. MMP-8 and >600 fold selectivity vs. MMP-2, and has a 4.8 h half-life in rats.
Matrix Metalloproteinases (MMPs) are a family of about 27 zinc-dependent enzymes responsible 
for the turnover of collagen in connective tissue. There are a variety of disease states where 
degradation of collagen contributes to the pathology, specifically, in osteo- and rheumatoid 
arthritis; in tumor angiogenesis and metastasis; in post-MI cardiovascular remodeling. In the 
previous Letter,1a we note that joint-stiffening, "musculoskeletal syndrome" (MSS), upon 
prolonged dosing with MMP inhibitors (MMPi’s) has prevented  approval of an MMPi. Efforts 
have been made to spare MMP isoforms that are thought to contribute to MSS, specifically, 
MMP-1 and -14 (MT1-MMP) (SD-2590, fig. 1),1b but a more focused approach toward realizing 
efficacious MMP inhibitors with reduced side effects should be to focus on optimizing a single 
MMP isoform that confers the most therapeutic benefit, reducing the probability of off-target 
protease binding. MMP-13, upregulated in osteoarthritic joints and in cancer, is an attractive 
isoform to target, and structural studies show that -13 differs from other MMP's deep in the S1' 
pocket, suggesting that lengthier inhibitors may confer selectivity.
With this in mind, we elaborated a series of rigid piperidino- ketones (compound 2, Figure 1) 
with  lengthier P1' subunits and, with optimization, we were able to achieve significant 
selectivity for MMP-13 vs. other MMP isoforms.2 Conceptually dissecting the piperidine ring in 
compound 2, we also wanted to explore acyclic-chain analogs such as amide 3 (Figure 1).1
While excellent MMP-13 selectivity (Table 1 ) was achieved with a number of amides related to 
compound 3, the amides displayed short half-life in rats, presumably due to hydrolytic cleavage 
of the amide bond. In an effort to prepare compounds with suitable selectivity and PK, we 
incorporated the SAR findings from the acyclic amide series into a small series of compounds 
where the amide is replaced by isosteric heterocycles. This Letter summarizes that effort.
Among the isosteres we wanted to consider were tetrazoles. Entry into this series began by 
alkylating the requisite 5-phenyl-1H-tetrazoles (e.g. 5, scheme 1) using O-tetrahydropyranyl-3-
chloropropanol. Alkylation afforded predominantly the desired 2-isomers for 5-[4-
methoxyphenyl]- and 5-[4-trifluoromethoxyphenyl]-tetrazole, and the products were purified by 
chromatography. The THP protecting group could be removed with acid and the product alcohol 
(e.g. 6) reacted with the known aryl fluoride 7.1 The t-butyl ester 8 was cleaved and the resulting 
acid reacted with O-tetrahydropyranyl hydroxylamine in the presence of EDC. Removal of the 
THP gave the desired hydroxamic acids 4b. In the case of 5-[4-methyl-2-pyridyl]-tetrazole, 
alkylation gave a 3:2 mixture, still favoring the 2-position. The poor selectivity in the alkylation 
step afforded us the opportunity to isolate meaningful quantities of both 2- and 1- isomers and to 
carry the isomers individually on to final product (4d and 4e, table 1).
Oxadiazoles (e.g 4f, Table 1) were prepared by combining the known acid 91 and 4-
(trifluoromethoxy)benzamidoxime in the presence of EDC, then heating the coupled product to 
close the ring. After condensation of the oxadiazole, the t-butyl ester (10, Scheme 2) is carried 
on to the hydroxamic acid employing the same transformations used for the tetrazoles.
From Table 1, we see that replacing the amide in 3 (Table 1) with various aryl heterocycle 
combinations: tetrazoles (4a-e); oxadiazoles (4f,g); and imidazoles (4h,i) continues to  
demonstrate high levels of selectivity for MMP-13 vs. MMP-1, -2, -7, -8, -9, and -14. Selectivity 
vs. MMP-3 is lowered. Unexpectedly, we see that the 1,5-isomer of the pyridyl analog (4e) has a 
selectivity profile very similar to its 2,5-substituted isomer (4d). These results inspired us to 
make some similarly disposed imidazoles (4j). We also made an isomeric 1,5-substituted 
tetrazole, where the tetrazole carbon connects to the acyclic chain, by a chemospecific method5 
(scheme 2) not involving N-alkylation (4j).
The crystal structure of tetrazole 4c was determined at 1.9Å resolution (Figure 2). 6 The 
selectivity in this series derives from the depth and flexibility of the MMP-13 S1’ pocket, which 
is distinct from other MMP family members such as MMP-1 and MMP-2, with shorter pockets. 
The tetrazole group forms a single direct hydrogen bond to the protein backbone at Thr245 
(3.0Å); the remainder of the side chain interactions with the protein are van der Waals contacts. 
The S1’ pocket of MMP-13 readily morphs to interact with inhibitors of various sizes and 
shapes, as we see in the case of tetrazoles 4d and 4e. We were able to achieve >103 selectivity vs. 
most other MMP family members with 4c, but even more specific compounds may be possible 
with this or other scaffolds.
We were able to improve on the 0.59 h half-life we measured for the lead amide compound 3; 
from Table 1, we see heterocyclic compounds with half-lifes ranging from 1.4 to 4.8 h, some 
compounds having good BA (e.g. tetrazole 4c, 26%; and oxadiazole 4f, 28%) and achieving 
encouraging Cmax. Based on our data, we believe selected heterocyclic analogs in this Letter 
would be promising drug candidates for the treatment of arthritis, cancer, and post-MI left 
ventricular hypertrophy (CHF).
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Figure 1. MMP inhibitors. Compound 1 (SD-2590) 
spares MMP-1; Compounds 2, 3, and 4a are MMP-
13 selective.
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Scheme 1. Reagents and Conditions:  (a) NaH (2.1 
eq), NMP, rt; then 2-(3-chloropropoxy)tetrahydro-2H-
pyran (1.1 eq) r.t. to 70°C (45%) (b) AcCl (3.8 eq), 
MeOH, rt (94%) (c) 6 (1.05 eq), NaH (1.1 eq), NMP, 
55°C, 1h (70%) (d) NaOH (50% aq, 10 eq), THF, 
EtOH, rt to 60°C, then acidify w/ HCl, conc., 
azeotrope CH3CN (e) triethylamine (XS), HOBT, 
THPONH2 (1.5 eq based on 7a), EDC (1.5), DMF, 
40 h (65%) (f) AcCl (4 eq), MeOH, trit. ether (74%)
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Scheme 2. Reagants and Conditions: (a) DMF, 
HOBT (1.4 eq), triethylamine (1.2 eq), 4-
(trifluoromethoxy)benzamideoxime (1.2 eq), EDC 
(1.5 eq), rt, 2h (b) toluene, 90°C, 30 h (c) HOBT 
(1.33 eq), 4-(trifluromethoxy)aniline (1.33 eq), EDC 
(1.33 eq), DMF, rt, 4 h (80%); (d) PPh3 (2.0 eq), 
dioxane; then DEAD (2.0 eq); then TMS-N3 (2.0 eq), 
rt, 16 h (66%).
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a.) MMP-1 and -14 >10k nM except for 1 (MMP-14 = 14 nM) and 4a (MMP-1 = 5600 nM).
b.) For 4a-k, X = O except: 4c, where X = NCH2CH2OMe and 4g, X = NCH2CH3
c.) IC50 instead of Ki.
31 >10k 180 1600 1.5
9.9 7100 72 1700 1.2
8.7 8600 8000 160 0.13
130 >10k 140 3.7>10k
59 6000 74 1800 1.7
Table 1: Selectivity and PK of heterocyclic MMP-13 selective analogs.
<0.1c 29c 7000 1.7c 0.2c <0.1c
R
R1 =
A B C D E
F G H
410 37 >10k 260 370 2.0
Rat PK
BA%  t1/2 (h)  Cmax ng/mL (MPK)  Cl (mL/min/kg)
1 N/A
N/A2
N/A3
4a
4b
4cb
4f
4gb
4d
4h
4e
4j
32 2.4
A
B
B
C
C
D
E
F
G
H
12
22
28 2.4
1.4 14
19
1.7 2.0 46
5.0 4.8 63
1.5 0.59 0.02 (20)
61 (1.5)
26 1.3 1400 (20)
240 (20)
2200 (20)
3500 (5)
3000 (5)
7.3 4.0 423500 (5)
4i
4200 (20)1.214
68 2.9 21900 (20)
Figure 2.  Structure of MMP-13 with compound 
4c bound at the catalytic site. The inhibitor 
binds deeply within the S1’ pocket of the active 
site and causes a conformational change 
opening the loop to accommodate the 
compound.  The hydroxamate moiety chelates 
the zinc ion at two positions, and Glu223 forms 
a hydrogen bond to the hydroxamate.  
Similarly, the hydroxamate nitrogen atom forms 
a hydrogen bond to the protein backbone, as 
does one of the sulfone oxygen atoms.  A 
single hydrogen bond is formed between the 
tetrazole and the protein backbone. A HEPES 
buffer molecule bound adjacent to the inhibitor 
in two of the four protein molecules in the 
crystal, and an array of solvent atoms form an 
auxiliary van der Waals surface between the 
inhibitor and the protein.6
Supplementary Material:
Rod shaped crystals of the MMP-13 in complex with tetrahydro-N-hydroxy-4-[[4-
(phenylmethyl)-1-piperazinyl]sulfonyl]-2H-pyran-4-carboxamide, hydrochloride (Getman, 
Daniel P.; Becker, Daniel P.; Barta, Thomas E.; Villamil, Clara I.; S. L. Hockerman; Bedell, 
Louis J.; Li, Madelleine H.; Freskos, John N.; Heintz, Robert M.; McDonald Joseph J. ; 
DeCrescenzo, Gary A. , “Thioaryl Sulfonamide Hydroxamic Acid Compounds” US 6,087,359, 
2000.) complex were grown at 4°C by sitting drop vapor diffusion using 5 mg/mL protein and a 
reservoir solution of 1.4M lithium sulfate, 0.1M Hepes, pH 7.7. The ratio of protein to reservoir 
solution in the crystallization drop was 5:1.  Crystals were pre-equilibrated in a soaking solution 
containing 1.5M lithium sulfate, 0.1M Hepes, pH 7.7 without inhibitor at room temperature for 
more than two hours. These crystals were then transferred to a second solution containing 1.5M 
lithium sulfate, 0.1M Hepes, pH 7.7 and 2.5mM of replacement inhibitor and were left to 
incubate at room temperature for several days. The cryo solution consisted of 20% sucrose, 1.5M 
lithium sulfate, and 0.1M Hepes, pH 7.7.  Data were collected using a Rigaku Micromax 007 X-
ray generator on a Mar Research MarCCD 165 detector.  The diffraction data were integrated 
and scaled with HKL-2000 (Otwinowski, Z. and Minor, W, (1997). In Methods in Enzymology, 
276, edited by C.W. Carter, Jr. & R.M. Sweet pp. 307-326, New York:Academic Press.), and the 
structures were determined by molecular replacement using a prior internal structure of MMP-13 
as the initial model.  The model adjustment occurred as in Kjeldgaard (Jones, T.A., Zou, J.Y., 
Cowan, S.W. and Kjeldgaard, M. Acta Cryst 1991 A47, 110-119.) and Coot (Emsley, P.; Cowtan, 
K. Acta Crystallographica Section D 2004, 60, 2126), and the structures were refined initially 
with X-PLOR (Brünger, A. T. 1992. X-plor version 3.1: a system for X ray crystallography and 
NMR. Yale University Press, New Haven, Conn.) and were further optimized in Refmac 
(Murshudov, G. N.; Vagin, A. A., and Dodson, E. I. Acta Cryst. 1997, D53, 240).
Crystallographic Data and Refinement Statistics
PDB accession code 3O2X
Data collection statistics
Radiation source
Radiation detector
Space group
Resolution (Å)
Observed reflections
Unique reflections
Completeness (%)
Mean I/σI
 Rsym%b
Refinement statistics
Resolution (Å)
No. protein + ligand atoms
No. solvent atoms
R (%), Rfree (%)
Wilson B (Å2), Refined <B> (Å2)
     Rmsd ideal bond lengths (Å)
     Bond angles (°)
Rotating anode
MAR CCD 165
P212121
20.0-1.9 (1.97-1.90)
271,723
56,980
84.3, 79.3
16.4, 3.8
8.4, 27.1
20-1.9
5,486
682
17.9, 21.1
12.9,
0.006
1.095
a Highest resolution bin. b Rsym = Σ(|Ii-<I>|)/ΣIi.  All reflections with I/σI < -1.0 eliminated from 
scaling. 
